Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / April / Shape-Changing IOL Shows Durability
Refractive Latest News

Shape-Changing IOL Shows Durability

Atia Vision reports positive 36-month data for its shape-changing IOL at ASCRS 2026

4/28/2026 2 min read

Share

  • Full Article
  • Summary
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Top Institutions

Three-Year Data Demonstrate Durability of Shape-Changing OmniVu IOL

Overview

The investigational OmniVu Lens System shows sustained refractive stability and a continuous range of vision through 36 months post-implantation. Visual acuity outcomes remain excellent with minimal safety concerns, supporting the potential of shape-changing, modular IOL designs in premium cataract surgery.

Background

Premium intraocular lenses (IOLs) aim to restore a broad range of vision following cataract surgery, addressing presbyopia and refractive errors. Traditional multifocal and accommodating IOLs often face challenges such as dysphotopsia, contrast sensitivity trade-offs, and stability of lens position. The OmniVu Lens System employs a novel two-part modular design with a fluid-filled, shape-changing base to mimic natural accommodation and a front optic for refractive correction. This approach seeks to improve refractive stability and reduce posterior capsule opacification.

Data Highlights

ParameterValue at 36 Months
Mean manifest refraction spherical equivalentWithin ±0.50 D
Mean binocular uncorrected distance visual acuity-0.11 logMAR (~20/16)
Best-corrected distance visual acuity-0.17 logMAR (~20/12)
Mean binocular uncorrected intermediate visual acuity-0.05 logMAR (20/20)
Mean binocular uncorrected near visual acuity0.06 logMAR (~20/25)
Defocus range with 20/32 or better vision~5.0 D continuous defocus
YAG capsulotomy rate1 event across all eyes and visits
Lens exchanges0
Refractive enhancements0

Key Findings

  • Mean manifest refraction spherical equivalent remained stable within ±0.50 D over 36 months.
  • Excellent visual acuity outcomes with mean binocular uncorrected distance acuity around 20/16 and best-corrected distance acuity approximately 20/12.
  • Continuous range of vision demonstrated by 20/32 or better visual acuity across ~5.0 D of defocus, covering distance through near vision.
  • Minimal safety concerns: only one YAG capsulotomy reported, with no lens exchanges or refractive enhancements required.
  • Early contrast sensitivity comparable to monofocal IOL benchmarks under mesopic conditions, indicating favorable visual quality.
  • Modular, fluid-filled design supports stable effective lens position and may reduce posterior capsule opacification.

Clinical Implications

The OmniVu Lens System's sustained refractive stability and broad continuous range of vision suggest it may offer a promising alternative to existing premium IOLs, particularly for patients seeking presbyopia correction with minimal visual disturbances. Its modular, shape-changing design could enhance lens position stability and reduce complications such as posterior capsule opacification, potentially improving long-term outcomes. Surgeons should monitor ongoing clinical trials to evaluate its future role in cataract surgery.

Conclusion

The three-year first-in-human data validate the durability and functional benefits of the OmniVu shape-changing IOL, highlighting its potential to advance premium cataract surgery. Continued clinical evaluation will clarify its place in the evolving presbyopia-correcting IOL landscape.

References

  1. Atia Vision/BusinessWire/2026 -- Three-Year Data for OmniVu Lens System Presented at ASCRS

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: